Lilly announced additional findings indicating that its rheumatoid arthritis drug, baricitinib, may improve the health of severe Covid-19 patients when used in combination with Gilead Science’s antiviral drug remdesivir.
Lilly’s Rheumatoid Arthritis Drug, Combined With Remdesivir, Benefits Covid-19 Patients Who Need Oxygen
